Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study. Monedero, P., Gea, A., Castro, P. et al. Crit Care 25, 2 (2021). https://doi.org/10.1186/s13054-020-03422-3
Ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. DOI: 10.1007/s00134-020-06330-w
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. JAMA. 2020;324(13):1330-1341. doi:10.1001/jama.2020.17023 DOI: 10.1001/jama.2020.17023
Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019. Villar, Jesús MD, PhD; Confalonieri, Marco MD; Pastores, Stephen M. MD, MACP, FCCP, FCCM; Meduri, G. Umberto MD. Critical Care Explorations: April 2020 – Volume 2 – Issue 4 – p e0111 DOI: 10.1097/CCE.0000000000000111
Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Villar, J., Ferrando, C., Martínez, D., Ambrós, A., Muñoz, T., Soler, J.A., et al The lancet Respiratory Medicine. Volume 8, Issue 3, P267-276, March 01, 2020DOI: 10.1016/S2213-2600(19)30417-5
Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials. Sterne, J.A.C., Diaz, J., Villar, J. et al. Trials 21, 734 (2020). 10.1186/s13063-020-04641-3